Octreotide: A Versatile Therapeutic Agent

Module 2

Expanding the Horizons of Octreotide Therapy

Table of Content

Octreotide in the Treatment of Endocrine Disorders	**2**
Octreotide: Novel Formulations and Delivery Systems	**4**
Emerging Applications of Octreotide	**7**
Combination Therapies	**12**
References	**16**

Octreotide: A Landmark in the Treatment of Endocrine Disorders

Since its creation two decades ago, octreotide (Sandostatin*), a powerful synthetic somatostatin analogue, has emerged as a primary medical treatment for endocrine disorders such as acromegaly and carcinoid syndrome, often associated with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Prior to octreotide's development, these rare hormonal disorders severely impacted patients' quality of life, with limited treatment options beyond surgery. The introduction of subcutaneous octreotide, followed by the long-acting release (LAR) formulation, marked a significant medical breakthrough. These advances enabled better control of excessive hormone secretion, resulting in remarkable improvements in patients' quality of life.

Acromegaly: A Revolution in Treatment

Acromegaly is a rare, chronic hormonal disorder caused by the excessive production of growth hormone (GH) by the pituitary gland, leading to an overproduction of insulin-like growth factor-I (IGF-I) in the liver. In over 90% of cases, this GH hypersecretion is due to a benign GH-secreting pituitary adenoma. Acromegaly increases the risk of severe comorbidities, including diabetes mellitus, hypertension, and cardiovascular disease. Physical deformities, such as enlarged hands and feet, frontal bone bossing, and coarse facial features, are also common. Moreover, patients with active acromegaly face a two- to three-fold increased risk of mortality.

Until the 1980s, the only treatments available were surgery, radiation therapy, and dopamine agonists. However, many tumors were too large or invasive to be fully resected, and dopamine agonists provided only minimal benefit, while radiation therapy took years to normalize hormone levels. Consequently, acromegaly remained uncontrolled in many patients. The introduction of octreotide in the early 1980s transformed acromegaly management, making the condition manageable in two-thirds of patients.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Carcinoid Syndrome

The management of patients with GEP-NETs, especially those with carcinoid syndrome, saw significant advancements with the arrival of octreotide. GEP-NETs are rare neoplasms originating from neuroendocrine cells in the digestive tract, pancreas, lungs, and liver. These tumors are characterized by the production of excessive peptide hormones and biogenic amines, which are normally regulated in much smaller amounts. Due to their slow progression, GEP-NETs may remain asymptomatic for years, with patients often presenting with vague abdominal pain, sometimes misdiagnosed as irritable bowel syndrome.

Treatment is typically initiated only when the most common type of GEP-NETs, well-differentiated nonpancreatic tumors (often called carcinoid tumors), metastasize to the liver, causing the clinical manifestations of carcinoid syndrome. Symptoms include severe flushing, debilitating diarrhea, and lower abdominal cramping. While therapies such as chemotherapy, radiotherapy, and surgery were used historically in GEP-NETs management, clinical outcomes remained poor until the development of octreotide. By suppressing the hormonal hypersecretion caused by GEP-NETs, octreotide not only lowers circulating hormone levels but also stabilizes tumor growth and significantly reduces symptoms. The introduction of octreotide LAR has further improved survival rates for patients with GEP-NETs.

Octreotide: A Milestone in Endocrine Therapy

Octreotide remains the most widely prescribed and thoroughly researched somatostatin analogue for the treatment of acromegaly and GEP-NETs. Its development marks a turning point in the management of these serious and rare hormonal disorders. Reflecting on the 20-year clinical experience with octreotide, it is clear that its impact on improving the quality of life for patients with acromegaly and GEP-NETs has been profound. From its initial development in the early 1980s to the launch of the long-acting formulation in 1997, octreotide continues to play an essential role in the therapeutic landscape, with promising potential for future applications in other conditions.

Octreotide: Novel Formulations and Delivery Systems

Sustained-Release Delivery and Clinical Applications of Octreotide

Octreotide, a synthetic somatostatin analogue, has revolutionized the treatment of neuroendocrine disorders such as acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). With advancements in its delivery systems, particularly through biodegradable polymeric microspheres, octreotide's efficacy and patient compliance have improved significantly.

Biodegradable Polymeric Microspheres for Sustained Drug Release

Poly(d,l-lactide-co-glycolide) (PLGA) is a biodegradable polymer composed of one or more hydroxy acid monomers, such as d-lactic, l-lactic, and glycolic acids. Depending on its formulation, it can range from highly crystalline to completely amorphous, making it a versatile material for drug delivery. Both PLA and PLGA formulations have demonstrated biocompatibility in therapeutic applications, causing no local or systemic adverse reactions.

The interest in biodegradable and biocompatible polymers has grown substantially due to their ability to control and prolong the action of therapeutic agents. These systems do not require removal from the body, as they degrade into compounds that are naturally excreted. Additionally, encapsulating drugs within these polymers protects them from degradation in the body, thus enhancing bioavailability.

PLGA microspheres are an advanced delivery system capable of providing controlled release of both small and large molecular weight molecules, including peptides, proteins, and DNA/RNA. Many commercial long-acting release (LAR) formulations now use PLGA microspheres for sustained drug release, offering advantages such as reduced dosing frequency, lower total doses, minimized side effects, and improved patient adherence.

Parenteral Versus Oral Administration

While oral drug delivery remains the preferred route of administration for many treatments, parenteral delivery offers significant advantages in certain cases, particularly when oral administration is challenging or ineffective. Parenteral delivery systems, especially sustained-release injectable formulations, offer extended drug release over days or even months. They

can reduce inter-subject variability caused by differences in oral absorption and metabolism, providing more consistent therapeutic outcomes.

Octreotide: From Short-Acting to Long-Acting Formulations

Octreotide is a cyclic octapeptide that has become a cornerstone in the medical management of neuroendocrine tumors, especially acromegaly and GEP-NETs. Its effectiveness in controlling symptoms of these disorders, including diarrhea and flushing in carcinoid syndrome, has made it a preferred treatment option. However, the short half-life of octreotide necessitated frequent injections, which posed a challenge for long-term management.

To address this, two types of commercially available octreotide formulations were developed. The first is a short-acting subcutaneous injection, administered three times daily, and the second is a long-acting release (LAR) formulation, administered intramuscularly on a monthly basis. The LAR formulation, made from PLGA microspheres, gradually releases the drug over time, allowing for extended therapeutic effects and reducing the need for frequent injections.

The sustained-release intramuscular formulation has become a valuable alternative to daily injections for managing chronic conditions such as acromegaly, where long-term therapy is required. This formulation offers significant benefits, including improved quality of life due to reduced dosing frequency and enhanced symptom control in patients with constant daily pain.

Octreotide and Long-Acting Repeatable (LAR) Octreotide Acetate

The use of somatostatin analogues to manage neuroendocrine disorders dates back to the late 1970s, when somatostatin was found effective in controlling diarrhea in patients with carcinoid syndrome. However, somatostatin's short half-life limited its clinical utility. In 1982, the development of octreotide, an octapeptide resistant to metabolic degradation, marked a breakthrough in somatostatin therapy. Octreotide acetate, the first commercially available somatostatin analogue, received approval in 1988 for the treatment of acromegaly, metastatic carcinoid tumors, and vasoactive intestinal peptide-secreting tumors.

Octreotide acetate is advantageous over endogenous somatostatin due to its longer half-life, which extends its duration of action up to 12 hours depending on the tumor type. However, even with this improvement, frequent dosing was still required. By 1998, a long-acting repeatable (LAR) formulation of octreotide acetate, administered intramuscularly every four

weeks, was approved. This LAR formulation releases octreotide gradually through the breakdown of the polymer matrix, maintaining therapeutic drug levels for extended periods.

Clinical Efficacy of Octreotide LAR

Clinical trials have shown that octreotide LAR is highly effective in controlling the symptoms of carcinoid syndrome, with over 70% of patients experiencing significant improvements in diarrhea and flushing. Moreover, dose optimization of octreotide LAR has proven to be safe, with mild to moderate side effects. Higher doses have also been used successfully in patients with uncontrolled symptoms or increasing tumor burden, without increasing adverse events.

Recent studies have confirmed that octreotide LAR is effective in managing patients with well-differentiated metastatic GEP-NETs of the midgut. This sustained-release formulation has demonstrated an antiproliferative effect, offering a valuable treatment option for patients requiring long-term therapy.

Octreotide LAR as Monotherapy

Several studies have highlighted the efficacy of octreotide LAR as a monotherapy for neuroendocrine tumors. A randomized trial comparing octreotide LAR with subcutaneous octreotide demonstrated comparable effectiveness in controlling symptoms of malignant carcinoid syndrome. Additionally, long-term studies have shown that octreotide LAR provides significant symptom relief in patients with metastatic NETs, with many patients experiencing tumor stabilization and improved quality of life.

The PROMID trial, a pivotal study investigating the antitumor effects of octreotide LAR, demonstrated that octreotide LAR significantly delayed tumor progression in patients with metastatic midgut NETs. While overall survival rates did not differ significantly, the trial showed improved survival in patients with lower hepatic tumor burden, emphasizing the importance of early intervention.

Conclusion

Octreotide, particularly in its long-acting repeatable formulation, has transformed the management of neuroendocrine tumors and acromegaly. Its ability to provide sustained symptom relief with fewer injections has improved the quality of life for patients requiring chronic therapy.

Use in Congenital Hyperinsulinism (CHI)

The use of somatostatin in treating congenital hyperinsulinism (CHI) was first reported in a child who underwent an 80% pancreatectomy, followed by its administration via continuous subcutaneous infusion in a 6-month-old infant with insulin excess. As new synthetic compounds with extended activity were developed, somatostatin receptor ligands (SRLs) like octreotide became available for patients with CHI who do not respond to diazoxide. For the past two decades, short-acting SRL octreotide has been effectively used as a second-line treatment for CHI to prevent hypoglycemia and avoid subtotal or near-total pancreatectomy. While SRLs are not typically used as a first-line treatment, they are considered when diazoxide is contraindicated or unavailable.

Octreotide is commonly administered via subcutaneous injections every 4 to 8 hours or through continuous infusions. However, early observational studies showed that doses of up to 40 mcg/kg/day were insufficient to prevent pancreatectomy in most patients. As the use of octreotide became more widespread, reports of improved outcomes and the ability to avoid surgery emerged, leading to its recognition as a standard, albeit off-label, therapy for CHI. Octreotide is now used in doses ranging from 5 to 40 mcg/kg/day, administered through bolus injections or continuous subcutaneous infusions via insulin pumps. While higher doses have been reported, most patients do not respond effectively beyond 20 mcg/kg/day. For those requiring frequent injections or higher doses, short-acting octreotide may be substituted with long-acting SRL formulations such as octreotide long-acting release (LAR) or lanreotide autogel.

Long-acting SRLs have been tested in small groups of patients with promising results. These formulations offer the advantage of reduced administration frequency, potentially improving the patient's quality of life. However, depot injections can be painful and inefficiently dosed, even when administered by trained staff. Although some observational studies have reported various markers of efficacy, the lack of a comparative control group makes it difficult to assess the true effectiveness of long-acting SRLs in achieving normoglycemia and harm-free survival. Additionally, no formal assessments have been conducted to evaluate the comparative benefits and risks of short- and long-acting SRLs, as their use falls outside standardized trial protocols.

Use in Insulinoma

Insulinomas are generally small, benign tumors that can often be surgically cured. However, managing metastatic insulinomas presents a more significant challenge. In addition to oral or intravenous glucose administration, several medical treatments are available to manage hypoglycemia in patients before surgery or in cases of metastatic disease. Diazoxide is a well-established medication used to manage hypoglycemia in insulinoma patients. It works by inhibiting insulin secretion through ATP-dependent potassium channels in pancreatic beta cells. Additionally, diazoxide increases hepatic glucose production and reduces glucose uptake by tissues, alleviating hypoglycemia in approximately 50-60% of cases. Treatment typically begins with low doses, gradually increasing as needed, but adverse effects such as water retention, hirsutism, weight gain, nausea, and headaches occur in about half of patients.

Somatostatin analogs (SSAs), including octreotide LAR and lanreotide autogel, are primarily used for malignant insulinomas, where activation of somatostatin receptors (SSTR) reduces insulin secretion. However, if SSTR expression is low or absent, SSAs may paradoxically lower blood glucose by inhibiting glucagon release.

Use in Polycystic Ovary Syndrome (PCOS)

In polycystic ovary syndrome (PCOS), hyperinsulinism is often observed alongside elevated luteinizing hormone (LH) levels. Somatostatin, which inhibits both insulin and LH secretion, has been investigated for its effects on gonadotropin and androgen levels in women with PCOS. A study involving 10 amenorrheic women with classic PCOS features examined the impact of treating them with octreotide, a long-acting somatostatin analog, administered subcutaneously at 100 micrograms twice daily for seven days.

The results showed that octreotide significantly reduced LH levels and pulse amplitudes, along with decreases in estradiol, testosterone, and androstenedione concentrations. LH responses to a gonadotropin-releasing hormone (GnRH) agonist were also diminished, and insulin and C-peptide responses to an oral glucose load were suppressed. These findings suggest that octreotide exerts its effects partly by directly influencing pituitary activity. The potential for indirect effects through changes in insulin levels also warrants further investigation. This research has important implications for the treatment of infertility in women with PCOS.

Use in Severe Postgastrectomy Dumping Syndrome

The therapeutic benefits of octreotide acetate in treating severe postgastrectomy dumping syndrome have been explored in both acute and chronic contexts. In an acute study, 10 patients were assessed using a double-blind, randomized design over two days. On one day, octreotide was administered subcutaneously at a dose of 100 micrograms, 30 minutes before a 'dumping breakfast.' On the other day, a placebo was given. A control group of postgastrectomy patients without dumping syndrome was also included for comparison.

The results demonstrated that during placebo treatment, the test meal led to significant increases in pulse rate and plasma levels of glucose, glucagon, pancreatic polypeptide, neurotensin, and insulin. In contrast, octreotide treatment successfully prevented the vasomotor and gastrointestinal symptoms associated with dumping syndrome and completely inhibited the associated plasma peptide responses. Moreover, octreotide eliminated diarrhea and suppressed the rise in plasma insulin, thereby preventing late hypoglycemia. Long-term daily treatment with octreotide resulted in minimal side effects, stable fasting plasma glucose levels, normal liver function, and an average weight gain of 11% over 12 months. Most patients were able to resume their regular work activities. Overall, octreotide acetate proved highly effective in preventing the symptoms of severe dumping syndrome.

Use in Chylothorax

Chylothorax, a rare but serious postoperative condition, particularly in pediatric patients following cardiac surgery, occurs when pleural effusion contains triglyceride-rich chyle. This condition arises due to a rupture in the thoracic duct, which channels lymphatic fluid from the body, including the gastrointestinal tract, into the left subclavian vein. In some cases, chylothorax is caused by increased systemic venous pressure or central vein thrombosis.

Octreotide, a synthetic somatostatin analog, has become a valuable tool in managing acquired chylothorax in recent years. Its proposed mechanism of action involves blocking lymph flow in the thoracic duct by influencing splanchnic circulation and gastrointestinal motility. Additionally, octreotide reduces hepatic venous pressure, intestinal lipid absorption, chyle concentrations in the thoracic duct, and splanchnic blood flow. Compared to somatostatin, octreotide has a longer half-life, greater potency, and the flexibility of subcutaneous administration.

In cases where chylothorax persists despite total parenteral nutrition (TPN), octreotide has been considered as an adjunct treatment, particularly when drainage exceeds 20 mL/kg/day. Studies have shown that octreotide significantly reduces total fluid loss, duration of chest tube usage, and postoperative hospital stays. Additionally, octreotide has been associated with shorter hospital stays in pediatric patients following cardiac surgery, with promising outcomes in reducing the duration of chylothorax and fluid drainage.

Use in Refractory Ascites

Ascites, a common complication of cirrhosis, often signals poor prognosis. The underlying pathophysiology involves arterial vasodilation, primarily within the splanchnic vasculature, reducing effective arterial blood volume. This leads to a compensatory activation of neurohumoral pressor systems, which contribute to renal sodium and water retention as well as renal vasoconstriction. While most cases of ascites can be managed through dietary sodium restriction and diuretics, approximately 5-10% of patients develop refractory ascites.

Octreotide has shown potential in improving renal function and diuretic response in patients with refractory ascites. It promotes arterial splanchnic vasoconstriction by inhibiting glucagon secretion. Moreover, octreotide has been found to suppress the release of renin and aldosterone, possibly through direct action on renin-producing cells and the adrenal glands. These combined effects support its utility in patients who do not respond well to traditional diuretic treatments.

Use in Gastrointestinal Motility Disorders

Octreotide has demonstrated efficacy in treating gastrointestinal motility disorders, particularly in conditions like scleroderma. In studies involving both healthy subjects and patients with scleroderma, octreotide has been shown to stimulate strong intestinal motor activity. While motility patterns in scleroderma patients are typically disorganized, octreotide helps coordinate aborally directed motor activity, similar to healthy individuals.

In patients suffering from gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and bloating, subcutaneous administration of octreotide (50 mcg/day) over a period of three weeks led to symptom improvement. Additionally, there was a significant reduction in bacterial overgrowth, as measured by breath hydrogen testing. Octreotide’s ability to reduce the perception of rectal distension without affecting motor pathways further emphasizes its

potential for enhancing tolerance to volume distension and alleviating symptoms in conditions such as irritable bowel syndrome.

Use in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Octreotide has become a cornerstone in the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While surgery remains the first-line treatment, a cure is often elusive, as most patients are diagnosed at advanced stages. For these individuals, palliative care aimed at improving quality of life becomes paramount, particularly in controlling symptoms like diarrhea and flushing.

Octreotide has demonstrated significant effectiveness in alleviating these symptoms. Data pooled from multiple trials have shown that up to 71% of patients experience relief from diarrhea and flushing during octreotide therapy. In patients with carcinoid syndrome, octreotide also plays a role in reducing 5-HIAA levels, a key metabolite of serotonin. By decreasing bioactive secretions from carcinoid tumors, octreotide effectively reduces the frequency of diarrhea and flushing episodes, thus lowering the risk of comorbidities such as dehydration and intestinal infections.

The long-acting formulation, octreotide LAR, has been particularly useful in maintaining long-term symptom control, promoting water and electrolyte absorption, reducing splanchnic blood flow, and prolonging gastrointestinal transit time. Although tumor shrinkage is rare, octreotide’s antiproliferative properties help in stabilizing the disease in many patients.

Combination Therapies

Everolimus and Octreotide LAR Combination Therapy

The PROMID study significantly impacted clinical practices by indicating that combination therapies, including somatostatin analogs, mammalian target of rapamycin (mTOR) inhibitors, and other forms of chemotherapy, could improve progression-free survival (PFS) in patients with neuroendocrine tumors (NETs), especially those who do not respond to somatostatin treatment alone or present with advanced disease and poor prognosis.

One such combination is everolimus (RAD001), an oral mTOR inhibitor, with octreotide LAR. Studies have shown that this combination has a positive impact on tumor cell proliferation. An open-label, Phase II trial in patients with refractory pancreatic NET demonstrated that the combination of everolimus and octreotide LAR enhanced antitumor effects compared to everolimus monotherapy.

The RADIANT-1 trial highlighted that patients treated with the combination therapy exhibited a median PFS of 16.7 months, compared to 9.7 months for those receiving only everolimus. These findings underscore the potential synergistic effects of combining octreotide LAR with other therapies, but further studies are needed to understand the full scope of this combination's role in improving tumor control.

Results from the RADIANT-2 Study

The RADIANT-2 trial, a double-blind, Phase III study, evaluated the effect of everolimus combined with octreotide LAR in patients with advanced NETs. This study showed a higher rate of chromogranin A (CgA) response in patients treated with everolimus plus octreotide LAR (45.7%) compared to those receiving placebo and octreotide LAR (28.8%). Additionally, the median PFS increased from 11.3 months in the placebo arm to 16.4 months in the combination therapy group. However, despite significant improvements in PFS and CgA response, the study did not show a notable difference in overall survival (OS) between the two groups.

Italian Trials in Medical Oncology (ITMO) Findings

In contrast to previous trials focusing on patients with advanced disease, the ITMO study conducted a Phase II trial using everolimus and octreotide LAR as a first-line treatment for NETs of gastroenteropancreatic and pulmonary origins, with or without carcinoid syndrome. This study achieved an objective response rate (ORR) of 18% in 50 patients, with 74% achieving stable disease, 16% achieving a partial response, and 2% showing a complete response. Subgroup analyses revealed no significant differences in ORR between patients with or without carcinoid syndrome or based on primary tumor site.

Indian Study Results

A separate study conducted in India over three years evaluated the combination therapy in 16 patients diagnosed with NETs. These patients, having undergone two or fewer lines of chemotherapy, were administered oral everolimus (10 mg/day) along with intramuscular octreotide LAR (30 mg every 28 days). The results demonstrated clinical benefits in 69% of patients, with 63% showing stable disease and 6% achieving partial response according to RECIST criteria.

The combination of everolimus and octreotide LAR has thus shown consistent safety and efficacy across retrospective and prospective trials, supporting its potential as a first-line treatment for advanced NETs and those who have not responded to other treatment modalities.

Radiotherapy with Radiolabeled Somatostatin Analogs

Peptide Receptor Radionuclide Therapy (PRRT)

Peptide receptor radionuclide therapy (PRRT) has been utilized for over two decades in the treatment of advanced NETs. This form of systemic radiotherapy specifically targets tumor cells that express high concentrations of somatostatin receptors. Among the most commonly used radiopeptides are 90Y-DOTATOC (a high-energy β emitter) and 177Lu-DOTATATE (a strong β/weak γ emitter). Other radionuclides, such as Bismuth-213, Actinium-225, and Indium-111, are less commonly used.

In one of the largest studies published on PRRT, 177Lu-DOTATATE treatment was administered to over 500 patients with metastatic gastroenteropancreatic NETs. The treatment was well-tolerated, and tumor remission rates included 2% complete remissions and 28% partial remissions. An additional 16% of patients experienced a significant reduction in tumor

size, ranging from 25% to 50%. The median overall survival (OS) for these patients was reported as 46 months from the start of treatment.

The NETTER-1 Trial: A Landmark in PRRT Research

The recently conducted NETTER-1 trial, an international, multicenter, open-label study, represents a landmark in PRRT research. The study randomly assigned 229 patients with well-differentiated, metastatic midgut NETs to receive either four intravenous infusions of 200 mCi (7.4 GBq) 177Lu-DOTATATE every eight weeks, followed by octreotide LAR 30 mg, or high-dose octreotide LAR 60 mg every four weeks as a control group.

Interim results showed that after 20 months, 65.2% of patients in the 177Lu-DOTATATE group exhibited progression-free survival (PFS) compared to only 10.8% in the high-dose octreotide LAR group. While the median PFS had not been reached in the 177Lu-DOTATATE group at the time of interim analysis, the control group exhibited a median PFS of 8.4 months. The 177Lu-DOTATATE group demonstrated a 79% lower risk of disease progression or death compared to the control group.

The trial also revealed a significantly higher tumor response rate based on RECIST criteria in the 177Lu-DOTATATE group (18%) compared to the control group (3%). Furthermore, the estimated risk of death was 60% lower in the 177Lu-DOTATATE group, with 14 deaths compared to 26 in the high-dose octreotide LAR group.

Long-Term Survival with Aggressive Cytoreductive Surgery and Octreotide LAR

Research has indicated that combining aggressive cytoreductive surgery with octreotide LAR can significantly enhance long-term survival outcomes for patients with metastatic neuroendocrine carcinoma originating from the gastrointestinal tract, including the small bowel and pancreas. A study involving 49 patients followed for a median of 112 months revealed remarkable disease-specific survival (DSS) rates: 94% at one year, 78% at five years, 64% at ten years, and 31% at fifteen years. In comparison, a cohort from the SEER-Medicare database during 2003 to 2009 demonstrated lower DSS rates for patients receiving surgery alone (54.7% at five years and 51.8% at ten years) and those treated with long-acting somatostatin analogs alone (50.0% at five years and 36.0% at ten years). In stark contrast, the DSS for the group receiving neither treatment was only 34.3% at five years and 26.3% at ten years.

Combination Therapies for Progressive Metastatic NETs

In an eight-year study assessing patients with progressive metastatic NETs who had been treated with octreotide LAR, researchers found that a subgroup of 59 out of 108 patients, who exhibited worsening clinical symptoms and/or radiographic assessment according to RECIST criteria, received additional combination therapies. These included treatments with Y-90-labeled somatostatin peptides, I-131 MIBG, transarterial hepatic embolization, and interferon. Remarkably, around 25% of these patients experienced an objective response, while the remainder achieved disease stabilization. Notably, the combination therapies were reported to be safe and well-tolerated. The overall PFS was observed at 85% after two years, 72% after three years, 57% after five years, and 36% after seven years, showing a statistically significant difference in PFS between patients receiving octreotide LAR alone and those requiring additional therapies.

Peptide Receptor Radionuclide Therapy with Lu-177 Octreotate

Treatment with somatostatin analogues has proven effective in providing significant symptomatic relief for patients with functional NETs by mitigating the hormonal hyperactivity. Data from the PROMID study demonstrated that treatment with octreotide LAR can lead to prolonged disease-free survival for patients with midgut carcinoid tumors. The study also reported reductions in biochemical markers, including chromogranin A, neurokinin A, serotonin in the bloodstream, and its metabolite (5-HIAA) in the urine.

Since the 1990s, peptide receptor radionuclide therapy (PRRT) has been utilized for treating patients with NETs, utilizing various radionuclides, including Indium-111 and Yttrium-90. However, Lutetium-177 has emerged as the radionuclide of choice in most therapy trials since the 2000s.

Lu-177 Octreotate (DOTATATE) PRRT employs the Lu-177 radionuclide, which is derived from Ytterbium and has a half-life of approximately 6.7 days. This radionuclide can deliver precise small doses of beta energies ranging from 0.149 to 0.479 MeV, allowing for localized radiation while minimizing collateral damage to surrounding normal tissues, especially compared to Yttrium-90. Lu-177 also emits two main gamma energies (0.113 MeV and 0.208 MeV), providing the necessary radiotracer for scintigraphic imaging, biodistribution assessments, and dosimetry studies during and after therapy.

References

- Rhee YS, Sohn M, Woo BH, Thanoo BC, DeLuca PP, Mansour HM. Sustained-release delivery of octreotide from biodegradable polymeric microspheres. AAPS PharmSciTech. 2011;12(4):1293-1301.
- Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics. 2017;11:115-122.
- Prelević GM, Wurzburger MI, Balint-Perić L, Nesić JS. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet. 1990;336(8720):900-903.
- Geer RJ, Richards WO, O'Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg. 1990;212(6):678-687. Bui A, Long CJ, Breitzka RL, Wolovits JS. Evaluating the Use of Octreotide for Acquired Chylothorax in Pediatric Critically Ill Patients Following Cardiac Surgery. J Pediatr Pharmacol Ther. 2019;24(5):406-415.
- Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol. 2006;41(1):118-121.
- Herrera-Martínez AD, Hofland J, Hofland LJ, et al. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2019;79(1):21-42.
- Hamiditabar M, Ali M, Roys J, et al. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017;42(6):436-443.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

CTS-77, Shop No.11, Swapna Siddhi CHS LTD, Akurli Road Near Malad Sahakari Bank
Kandivali (E), Mumbai - 400101. M: 9322615653 I W: www.wmefi.co.in